Drugs Affecting Blood and Blood Formation Practice Questions

Q: What is the most common adverse effect associated with ticlopidine?

Diarrhea. **Explanation:** Ticlopidine is a first-generation P2Y12 receptor antagonist (thienopyridine) that inhibits ADP-induced platelet aggregation. **1. Why Diarrhea is the correct answer:** While ticlopidine is notorious for its hematological toxicities, **diarrhea** is statistically the **most common** adverse effect, occurring in approximately 12–20% of patients. It is often dose-dependent and typically occurs within the first few weeks of treatment. Other frequent gastrointestinal disturbances include nausea and dyspepsia. **2. Analysis of Incorrect Options:** * **Neutropenia (Option A):** This is the most **serious** and characteristic side effect, occurring in about 2.4% of patients (severe in 0.8%). Because it can be life-threatening, it requires mandatory CBC monitoring every two weeks for the first three months. However, it is less frequent than diarrhea. * **Hemorrhage (Option C):** While bleeding is a risk with any antiplatelet agent, it is not the most common side effect specific to ticlopidine compared to GI upset. * **Thrombocytopenic Purpura (TTP) (Option D):** Ticlopidine is associated with rare but severe TTP. While high-yield for exams due to its severity, its incidence is very low (approx. 1 in 2,000 to 5,000 patients). **NEET-PG High-Yield Pearls:** * **Mechanism:** Irreversible blockade of P2Y12 (ADP) receptors. * **Clinical Shift:** Ticlopidine has been largely replaced by **Clopidogrel** because clopidogrel has a better safety profile (lower risk of neutropenia and TTP) and fewer GI side effects. * **Monitoring:** If ticlopidine is used, frequent monitoring of WBC counts is essential during the first 90 days. * **Pro-drug:** Like clopidogrel, ticlopidine is a pro-drug requiring hepatic activation.

Q: Which of the following is the mechanism of action of Pentasaccharide?

Factor Xa inhibition. **Explanation:** **Pentasaccharide (Fondaparinux)** is a synthetic anticoagulant that represents the minimum sequence of heparin required to bind to Antithrombin III. 1. **Mechanism of Action (Why B is correct):** Fondaparinux binds selectively and reversibly to **Antithrombin III (AT-III)**. This binding induces a conformational change in AT-III, which significantly increases its affinity for **Factor Xa**. Once bound, AT-III neutralizes Factor Xa, thereby inhibiting the conversion of prothrombin to thrombin and halting the coagulation cascade. Unlike Heparin, the pentasaccharide chain is too short to bridge AT-III to Thrombin (Factor IIa); therefore, it has **zero activity against Thrombin.** 2. **Analysis of Incorrect Options:** * **Option A & D:** These describe the action of **Unfractionated Heparin (UFH)**. UFH has a long polysaccharide chain (>18 units) that allows it to inhibit both Factor Xa and Thrombin (IIa) in a 1:1 ratio. * **Option C:** This is factually incorrect. Pentasaccharide is an **Antithrombin activator/agonist**, not an inhibitor. It utilizes Antithrombin to achieve its effect. **High-Yield Clinical Pearls for NEET-PG:** * **HIT Safety:** Fondaparinux does not bind to Platelet Factor 4 (PF4); therefore, it carries a negligible risk of **Heparin-Induced Thrombocytopenia (HIT)**. * **Monitoring:** Unlike UFH, it does not require routine aPTT monitoring due to its predictable pharmacokinetics. * **Elimination:** It is excreted unchanged by the kidneys; thus, it is **contraindicated in severe renal failure** (CrCl <30 mL/min). * **Antidote:** There is no specific reversal agent (Protamine sulfate does not work for Fondaparinux).

Q: Which one of the following preferentially activates plasminogen bound to fibrin and avoids the systemic lytic state?

Alteplase. **Explanation** The correct answer is **Alteplase (Option D)**. **1. Why Alteplase is Correct:** Alteplase is a recombinant **Tissue Plasminogen Activator (tPA)**. The fundamental pharmacological property that distinguishes it from older thrombolytics is its **"fibrin specificity."** Alteplase has a high affinity for plasminogen that is already bound to a fibrin clot. It converts this clot-bound plasminogen into active plasmin, leading to localized thrombolysis. Because it has low affinity for free-circulating plasminogen, it minimizes the systemic conversion of plasminogen to plasmin, thereby reducing the "systemic lytic state" and the associated risk of generalized bleeding. **2. Why Other Options are Incorrect:** * **Streptokinase (A):** This is a non-fibrin-specific thrombolytic derived from Beta-hemolytic Streptococci. It binds to both circulating and clot-bound plasminogen equally, leading to massive systemic depletion of fibrinogen and a high risk of systemic hemorrhage. * **Aminocaproic acid (B) & Tranexamic acid (C):** These are **antifibrinolytics**. They inhibit plasminogen activation and are used to *treat* excessive bleeding (e.g., in overdose of thrombolytics), not to induce clot lysis. **3. NEET-PG High-Yield Pearls:** * **Fibrin-Specific Agents:** Alteplase, Reteplase, and Tenecteplase (Tenecteplase is the most fibrin-specific and has the longest half-life, allowing bolus dosing). * **Non-Specific Agents:** Streptokinase and Urokinase. * **Antidote for Thrombolytics:** If life-threatening bleeding occurs, use Epsilon-aminocaproic acid (EACA) or Tranexamic acid. * **Clinical Note:** Despite fibrin specificity, all thrombolytics still carry a risk of intracranial hemorrhage.

Q: Which of the following is true regarding clopidogrel when compared to ticlopidine?

Clopidogrel is less likely to cause neutropenia.. **Explanation:** Both Clopidogrel and Ticlopidine are **P2Y12 receptor antagonists** (thienopyridines) that inhibit ADP-induced platelet aggregation. While they share the same mechanism of action, their side effect profiles differ significantly. **1. Why Option B is Correct:** Ticlopidine is associated with severe hematological toxicities, most notably **life-threatening neutropenia** (occurring in ~1% of patients) and agranulocytosis. It requires frequent monitoring of complete blood counts (CBC) during the first three months of therapy. **Clopidogrel**, a second-generation thienopyridine, was developed specifically to improve safety; it has a much lower incidence of bone marrow suppression and neutropenia, making it the preferred clinical choice. **2. Why the Other Options are Incorrect:** * **Option A:** Neither drug is typically associated with the formation of antiplatelet antibodies. This mechanism is more characteristic of Heparin-Induced Thrombocytopenia (HIT). * **Option C:** Clopidogrel does not inherently cause more severe bleeding than ticlopidine; both carry a similar risk of hemorrhage as a consequence of their antiplatelet action. * **Option D:** At standard clinical doses, both drugs provide comparable levels of maximal platelet inhibition. The primary advantage of clopidogrel is its **safety profile**, not superior efficacy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Both are **irreversible** inhibitors of the P2Y12 ADP receptor. * **Metabolism:** Clopidogrel is a **prodrug** activated by the hepatic enzyme **CYP2C19**. Genetic polymorphisms in CYP2C19 or concurrent use of **Omeprazole** (a CYP2C19 inhibitor) can reduce its clinical efficacy. * **Ticlopidine Side Effects:** Neutropenia, TTP (Thrombotic Thrombocytopenic Purpura), and severe GI upset. * **Prasugrel/Ticagrelor:** Newer agents that are more potent and have a faster onset of action than clopidogrel.

Q: Ticagrelor is a type of:

P2Y12 receptor blocker. **Explanation:** **Ticagrelor** is a potent antiplatelet agent that acts as a **direct-acting, reversible P2Y12 receptor antagonist**. [1] It inhibits the binding of Adenosine Diphosphate (ADP) to the P2Y12 receptor on the platelet surface, preventing the activation of the GPIIb/IIIa complex and subsequent platelet aggregation. Unlike Clopidogrel and Prasugrel, Ticagrelor is a **cyclopentyl-triazolo-pyrimidine** (not a thienopyridine) and does not require metabolic activation (it is not a prodrug). [1] **Analysis of Incorrect Options:** * **A. Cyclooxygenase (COX) inhibitor:** This describes **Aspirin**, which irreversibly inhibits COX-1 to prevent the synthesis of Thromboxane A2. [4] * **B. Phosphodiesterase (PDE) inhibitor:** This describes drugs like **Dipyridamole** or **Cilostazol**, which increase intracellular cAMP levels to inhibit platelet aggregation. [3] * **C. Glycoprotein IIb/IIIa inhibitor:** This describes intravenous agents like **Abciximab, Eptifibatide, and Tirofiban**, which block the final common pathway of platelet aggregation (fibrinogen binding). [2] **High-Yield Clinical Pearls for NEET-PG:** * **Reversibility:** Ticagrelor is the only oral P2Y12 inhibitor that is **reversible**, allowing for faster recovery of platelet function compared to Clopidogrel. [1] * **Adverse Effects:** A unique and high-yield side effect of Ticagrelor is **Dyspnea** (due to inhibition of adenosine reuptake) and occasionally **Bradyarrhythmias/Ventricular pauses**. * **Metabolism:** It is metabolized by **CYP3A4**; therefore, strong CYP3A4 inhibitors/inducers can significantly alter its plasma levels. * **Clinical Use:** It is a preferred agent in **Acute Coronary Syndrome (ACS)** and during Percutaneous Coronary Intervention (PCI).

Q: Heparin is a commonly used anticoagulant in cardiac surgery. All of the following statements about heparin are true EXCEPT:

It is the weakest acid found in living beings.. ### Explanation **1. Why Option A is the Correct Answer (The False Statement):** Heparin is actually the **strongest organic acid** found in the human body. It is a highly sulfated glycosaminoglycan with a high density of negative charges. This strong electronegativity is fundamental to its function, as it allows heparin to bind to various proteins, including antithrombin III and coagulation factors. **2. Analysis of Incorrect Options (True Statements):** * **Option B:** Commercial heparin is primarily sourced from **porcine (pig) intestinal mucosa** or bovine (cow) lung. Porcine heparin is more commonly used today. * **Option C:** Heparin acts as an indirect anticoagulant. It binds to **Antithrombin III (AT-III)**, inducing a conformational change that accelerates the inactivation of thrombin (Factor IIa) and Factor Xa by nearly 1,000-fold. * **Option D:** Heparin-Induced Thrombocytopenia (HIT) is a significant adverse effect. **Type II HIT** is an immune-mediated reaction where antibodies form against the Heparin-Platelet Factor 4 (PF4) complex, leading to platelet consumption and a paradoxical prothrombotic state. **3. Clinical Pearls for NEET-PG:** * **Monitoring:** Unfractionated Heparin (UFH) is monitored using **aPTT** (Target: 1.5–2.5 times the control). * **Antidote:** **Protamine sulfate** (a basic protein) neutralizes heparin via a chemical antagonism (acid-base reaction). * **Safety in Pregnancy:** Heparin is the **anticoagulant of choice in pregnancy** because its high molecular weight prevents it from crossing the placenta (unlike Warfarin, which is teratogenic). * **LMWH vs. UFH:** Low Molecular Weight Heparin (e.g., Enoxaparin) mainly inhibits Factor Xa and does not require routine aPTT monitoring.

Question 1

What is the most common adverse effect associated with ticlopidine?

Accepted Answer

Diarrhea

Answer

Neutropenia

Answer

Hemorrhage

Answer

Thrombocytopenic purpura

Question 2

Which of the following is the mechanism of action of Pentasaccharide?

Accepted Answer

Factor Xa inhibition

Answer

Factor Xa inhibition and Thrombin inhibition

Answer

Antithrombin inhibitor

Answer

Thrombin inhibition

Question 3

Which one of the following preferentially activates plasminogen bound to fibrin and avoids the systemic lytic state?

Accepted Answer

Alteplase

Answer

Streptokinase

Answer

Aminocaproic acid

Answer

Tranexamic acid

Question 4

Which of the following is true regarding clopidogrel when compared to ticlopidine?

Accepted Answer

Clopidogrel is less likely to cause neutropenia.

Answer

Clopidogrel is more likely to cause formation of antiplatelet antibodies.

Answer

Clopidogrel is more likely to cause severe bleeding.

Answer

Clopidogrel has a greater antiplatelet effect.

Question 5

What is the drug of choice for deep vein thrombosis (DVT)?

Accepted Answer

Low molecular weight heparin (LMWH)

Answer

Heparin

Answer

Acenocoumarol

Answer

Aspirin

Question 6

Which of the following statements about oral anticoagulants is FALSE?

Accepted Answer

They interfere with an early step in the synthesis of clotting factors.

Answer

Irrespective of the dose administered, their anticoagulant effect has a latency of onset of 1-3 days.

Answer

Their dose is adjusted by repeated measurement of prothrombin time.

Answer

They are contraindicated during pregnancy.

Question 7

Ticagrelor is a type of:

Accepted Answer

P2Y12 receptor blocker

Answer

Cyclooxygenase inhibitor

Answer

Phosphodiesterase inhibitor

Answer

Glycoprotein IIb/IIIa inhibitor

Question 8

Aspirin is not given to a patient already on heparin because aspirin causes:

Accepted Answer

Platelet dysfunction

Answer

Aspirin inhibits the action of heparin

Answer

Enhanced hypersensitivity to heparin

Answer

Heparin therapy cannot be monitored

Question 9

Heparin is a commonly used anticoagulant in cardiac surgery. All of the following statements about heparin are true EXCEPT:

Accepted Answer

It is the weakest acid found in living beings.

Answer

Most commercial preparations of heparin are derived from pig intestine.

Answer

It acts by antithrombin activation.

Answer

It can produce thrombocytopenia.

Question 10

Thrombolytic therapy with streptokinase is contraindicated in all of the following conditions EXCEPT?

Accepted Answer

Supraventricular tachycardia

Answer

Recent trauma

Answer

Recent cerebral bleeding

Answer

Recent surgery

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?